アブストラクト | BACKGROUND: Interstitial lung disease (ILD) events associated with anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have aroused wide attention. RESEARCH DESIGN AND METHODS: In meta-analysis, we systematically reviewed literatures, and the outcomes were the proportion and risk of ILD related to anti-HER2 ADCs. A disproportionality analysis based on data from VigiBase was conducted to characterize the main features of anti-HER2 ADC-related ILD/pneumonitis. RESULTS: Two hundred and forty-five all-grade and 47 grade >/= 3 ILD events with the proportion of 4.4% (95% confidence interval (CI) [2.0%, 6.8%]) and 0.5% (95% CI [0.3%, 0.8%]) were observed for anti-HER2 ADCs, respectively. Trastuzumab emtansine, trastuzumab deruxtecan and trastuzumab duocarmazine significantly increased the risk of all-grade and grade >/= 3 ILD events with Peto odd ratios of 2.62 (95% CI [1.71, 4.04], P < 0.0001) and 2.82 (95% CI [1.07, 7.42], P = 0.04), respectively. In VigiBase, 271 cases of ILD/pneumonitis related to trastuzumab emtansine and trastuzumab deruxtecan were extracted. The median time to the onset of event was 86 days and 54.95% of events occurred within 3 months. CONCLUSIONS: Trastuzumab emtansine, trastuzumab deruxtecan and trastuzumab duocarmazine increased the risk of ILD, which can lead to serious outcomes and tends to occur early. |
ジャーナル名 | Expert review of clinical pharmacology |
Pubmed追加日 | 2022/9/17 |
投稿者 | Ma, Zhuo; Zhang, Yi; Zhu, Min; Feng, Lin; Zhang, Yuhui; An, Zhuoling |
組織名 | Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University,;Beijing, China.;Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital,;Capital Medical University, Beijing Institute of Respiratory Medicine, Beijing,;China.;Department of Clinical Epidemiology, Beijing Chaoyang Hospital, Capital Medical;University, Beijing Institute of Respiratory Medicine, Beijing, China. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36111954/ |